Business
COYA 301 COYA 301, our low-dose interleukin 2 (IL-2) product candidate, is a biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo.
Coya Therapeutics, Inc.: Revenue grew 123.6% to $7.946M from $3.554M. Net loss widened to $21.23M from $14.88M. Operating cash flow outflow widened to $10.74M from $10.29M. Operating margin expanded 20148 bps to -283.87%. Coya Therapeutics, Inc.'s annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 123.6% to $7.946M from $3.554MOK
- Profitability — Net loss widened to $21.23M from $14.88MWatch
- Cash flow — Operating cash flow outflow widened to $10.74M from $10.29MNote
- Margins — Operating margin expanded 20148 bps to -283.87%OK
- Accounting — Distress-range screen needs contextWatch
- Insiders — 0 purchases and 0 salesNote
Leadership changes
From Coya Therapeutics, Inc.'s own filings, the day they're filed.
- Mark H. Pavao · director · departureeff. 2026-04-01
- Howard Berman · directors · departureeff. 2026-04-01
- Arun Swaminathan · Chief Executive Officer · appointmenteff. 2024-11-01
Latest filings
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-06-25
- DEF 14A · Annual proxy (pay & governance)2026-05-13
- 8-K · Company announcement2026-05-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Coya Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.